1. nab-Paclitaxel promotes elevated intratumoral gemcitabine levels.
nab-Paclitaxel promotes elevated intratumoral gemcitabine levels. A, 2′,2′-difluorodeoxcytidine:2′,2′-difluorodeoxyuridine (dfdC:dFdU) ratio in bulk tumor was quantified in mice 2 hours after the last dose of gemcitabine. (n ≥ 12). B, intratumoral levels of dFdCTP were measured in duplicate samples from mice in each cohort 2 hours after the last dose of gemcitabine. (n ≥ 12) C, intratumoral levels of paclitaxel were measured in samples from mice in each cohort 4 hours after the last dose of nab-paclitaxel (n ≥ 7). D, 2 KPC cell lines were pretreated with 10 μmol/L paclitaxel or dimethyl sulfoxide for 36 hours or 10 μmol/L tetrahydrouridine (THU; cytidine deaminase inhibitor) for 30 minutes as a positive control and incubated with 1 μmol/L gemcitabine for 2 hours. Levels of dFdCTP were then measured. Data are representative of 3 independent experiments. G, gemcitabine; nP + G, nab-paclitaxel and gemcitabine.
Kristopher K. Frese et al. Cancer Discovery 2012;2:
©2012 by American Association for Cancer Research